Kesimpta 20mg/0.4mL SDPF Syringe (Ofatumumab 20mg/0.4mL SDPF Syringe)

Multiple Sclerosis (MS)
– Relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease
Initial Dose
– 20 mg SC at Weeks 0, 1, and 2
Maintenance Dose
– 20 mg SC once monthly starting at Week 4
Manufacturer: Novartis
Administration
– SC administration only
– Administer SC in abdomen, thigh, or outer upper arm
– Do not inject into moles, scars, stretch marks or skin that is tender, bruised, red, scaly, or hard
– Perform first injection under guidance of a healthcare professional
– Sensoready pens and syringes are for single-dose only; discard after use
Missed Dose

– Administer as soon as possible without waiting until next scheduled dose
– Administer subsequent doses at recommended intervals

Preparation
– Remove syringe or pen from refrigerator and allow to reach room temperature 15-30 min; do not remove needle cover from prefilled syringe
– To avoid foaming, do not shake
– Visually inspect for particulate matter and discoloration; do not use if liquid contains visible particles or is cloudy
Storage
– Refrigerate at 2-8ºC (36-46ºF)
– Do not freeze
– Keep in original carton to protect from light
– To avoid foaming, do not shake